Infliximab is typically administered intravenously via 2- to 3-hour duration infusions.
Infusions are time-consuming and costly.
Shorter duration infusions are administered at some centers.
Limited safety data are available on shorter duration infusions.
Dr Neef and colleagues from Michigan, USA determined risk of infusion reaction associated with standard 2- to 3-h infusions vs. rapid infusions in patients receiving infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, spondylarthopathy and psoriatic disease.
MEDLINE, Embase, and Web of Science were searched.
Inclusion required human subjects, documentation of number of standard and rapid infliximab infusions and number of incident infusion reactions.
The team reported that 3 reviewers independently extracted data.
|9 studies compared the risk of infusion reaction in standard vs. 1-hour infusions|
|Alimentary Pharmacology & Therapeutics|
Study quality was assessed.
Relative risk was pooled using random effects models.
The researchers identified 10 studies comprising 13,147 standard 2- to 3-hours, and 8497 1-hour or less of infliximab infusions.
The team noted that 9 studies compared the risk of infusion reaction in standard vs. 1-hour infusions, demonstrating decreased relative risk of infusion reaction with 1-hour vs. standard infusions.
The research team noted that 7 studies limited to inflammatory bowel disease also demonstrated decreased risk of reaction.
Other comparisons demonstrated no difference in RR of reaction, including concomitant medication use or analysis limited to high and medium quality studies.
Dr Neef's team concludes, "Rapid infliximab infusions of ≤1-h duration are not associated with increased risk of infusion reaction when compared to standard 2- to 3-hour infusions in selected patients who previously tolerated 3 to 4 standard infusions."
"One-hour infusions will conserve health care resources and may lead to improved adherence and quality of life in patients receiving infliximab."